Cargando…

Longitudinal dynamics of the HIV-specific B cell response during intermittent treatment of primary HIV infection

BACKGROUND: Neutralizing antibodies develop in natural HIV-1 infection. Their development often takes several years and may rely on chronic virus exposure. At the same time recent studies show that treatment early in infection may provide opportunities for immune preservation. However, it is unknown...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Bree, Godelieve J., Wheatley, Adam K., Lynch, Rebecca M., Prabhakaran, Madhu, Grijsen, Marlous L., Prins, Jan M., Schmidt, Stephen D., Koup, Richard A., Mascola, John R., McDermott, Adrian B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5351995/ https://www.ncbi.nlm.nih.gov/pubmed/28296911 http://dx.doi.org/10.1371/journal.pone.0173577

Ejemplares similares

HIV-1 dual infection is associated with faster CD4+T cell decline in a cohort of men with primary HIV infection
por: Cornelissen, Marion, et al.
Publicado: (2011)

Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment
por: Dijkstra, Maartje, et al.
Publicado: (2021)

Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection
por: Vlot, Mariska C., et al.
Publicado: (2018)

Sequential staining of HIV gp140 to capture antigen-specific human B cells via flow cytometry
por: Townsley, Samantha M., et al.
Publicado: (2021)

Temporary Treatment during Primary HIV Infection Does Not Affect Virologic Response to Subsequent Long-Term Treatment
por: Grijsen, Marlous L., et al.
Publicado: (2014)

P04-49 LB. Adaptation of HIV-1 envelope glycoprotein to humoral immunity at a population level
por: Bunnik, EM, et al.
Publicado: (2009)

Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection
por: van Paassen, Pien, et al.
Publicado: (2022)

No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial
por: Grijsen, Marlous L., et al.
Publicado: (2012)

Loss of Circulating CD4 T Cells with B Cell Helper Function during Chronic HIV Infection
por: Boswell, Kristin L., et al.
Publicado: (2014)

Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial
por: Sarwar, Uzma N., et al.
Publicado: (2014)

Myeloid and plasmacytoid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4(+) T cells
por: Loré, Karin, et al.
Publicado: (2005)

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012)
por: Crank, Michelle C., et al.
Publicado: (2016)

How persistent stigma and discrimination keep people with visible skin diseases out of jobs: vitiligo in Brazil today
por: Silveira, Luísa Polo, et al.
Publicado: (2023)

Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men
por: Dijkstra, Maartje, et al.
Publicado: (2017)

Correction to: Development and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men
por: Dijkstra, Maartje, et al.
Publicado: (2017)

HIV transmission among acutely infected participants of a Dutch cohort study 2015–2021 is not associated with large, clustered outbreaks
por: Prins, Henrieke A.B., et al.
Publicado: (2023)

Defining B Cell Immunodominance to Viruses
por: Angeletti, Davide, et al.
Publicado: (2017)

Understanding Reasons for HIV Late Diagnosis: A Qualitative Study Among HIV-Positive Individuals in Amsterdam, The Netherlands
por: Bedert, Maarten, et al.
Publicado: (2021)

Reconsidering Early HIV Treatment and Supervised Treatment Interruptions
por: Koup, Richard A
Publicado: (2004)

Estimating the potential to prevent locally acquired HIV infections in a UNAIDS Fast-Track City, Amsterdam
por: Blenkinsop, Alexandra, et al.
Publicado: (2022)

Mosaic nanoparticle display of diverse influenza virus hemagglutinins elicits broad B cell responses
por: Kanekiyo, Masaru, et al.
Publicado: (2019)

The Cat and Mouse of HIV-1 Antibody Escape
por: Mascola, John R.
Publicado: (2009)

Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants
por: Huang, Yunda, et al.
Publicado: (2021)

The unbreakable journey: using photovoice to raise awareness and fight leprosy stigma in Papua, Indonesia
por: Dien, Ragil, et al.
Publicado: (2023)

Discontinuation of Intermittent Hemodialysis in HIV-Associated Nephropathy Following Initiation of Antiretroviral Therapy
por: Ghandour, Mohamedanwar, et al.
Publicado: (2021)

The deficiency in Th2-like Tfh cells affects the maturation and quality of HIV-specific B cell response in viremic infection
por: Noto, Alessandra, et al.
Publicado: (2022)

Virological and immunological correlates of HIV posttreatment control after temporal antiretroviral therapy during acute HIV infection
por: van Paassen, Pien M., et al.
Publicado: (2023)

Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study
por: Bil, Janneke P., et al.
Publicado: (2016)

Characterizing the fitness cost of viral escape from the HIV-1 broadly neutralizing monoclonal antibody VRC01
por: Lynch, RM, et al.
Publicado: (2012)

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)
por: Ledgerwood, JE, et al.
Publicado: (2009)

The changing face of HIV vaccine research
por: Kwong, Peter D, et al.
Publicado: (2012)

Fusion peptide priming reduces immune responses to HIV-1 envelope trimer base
por: Corrigan, Angela R., et al.
Publicado: (2021)

Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
por: González, Nuria, et al.
Publicado: (2018)

Accurate Prediction for Antibody Resistance of Clinical HIV-1 Isolates
por: Rawi, Reda, et al.
Publicado: (2019)

Neural dynamics of selective attention deficits in HIV-associated neurocognitive disorder
por: Lew, Brandon J., et al.
Publicado: (2018)

HIV integration and T cell death: additional commentary
por: Cooper, Arik, et al.
Publicado: (2013)

Soluble prefusion-closed HIV-envelope trimers with glycan-covered bases
por: Olia, Adam S., et al.
Publicado: (2023)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Monitoring Recently Acquired HIV Infections in Amsterdam, The Netherlands: The Attribution of Test Locations
por: Slurink, Isabel A. L., et al.
Publicado: (2021)

A 95% decline in estimated newly acquired HIV infections, Amsterdam, 2010 to 2022
por: van Sighem, Ard, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a5s2v1bn4dnru92875a36mbh14